Despite increasing therapeutic options and evolving treatment strategies, including targeting 3 therapeutic pathways, in the management of pulmonary arterial hypertension (PAH), morbidity and mortality have remained unacceptably high. Sotatercept is a first-in-class, novel activin signaling inhibitor approved for treating PAH based on evolving efficacy and safety evidence. This state-of-the-art review summarizes the current understanding of the mechanism of action, the impact on outcomes that improve how patients feel, function, and survive, and the safety and adverse event profile to inform readers of this breakthrough novel therapy.

中文翻译：

---

新的一天已经到来：用于治疗肺动脉高压的 Sotatercept。


尽管治疗选择不断增加，治疗策略也在不断发展，包括针对 3 种治疗途径，但在肺动脉高压 （PAH） 的管理中，发病率和死亡率仍然高得令人无法接受。Sotatercept 是一种同类首创的新型激活素信号转导抑制剂，根据不断发展的疗效和安全性证据被批准用于治疗 PAH。本最新综述总结了目前对作用机制的理解，对改善患者感觉、功能和生存方式的结局的影响，以及安全性和不良事件概况，以告知读者这种突破性的新型疗法。